Literature DB >> 1610398

Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions.

A J Lawrence1, A Michalkiewicz, J S Morley, K MacKinnon, D Billington.   

Abstract

The major metabolites of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), possess significant pharmacological properties. Whilst both metabolites bind to mu-opioid binding sites, M6G is a potent agonist whereas M3G antagonizes some of the effects of morphine and M6G. An inter-species comparison of in vitro hepatic morphine processing was performed. The results showed that not all species were able to produce M6G whereas all those tested did produce M3G. Guinea-pig liver produced the greatest amounts of M6G and was therefore chosen as a model to study morphine glucuronidation in further detail. Inclusion of the detergent Brij 58 (0.33 mg/mg protein) and Mg2+ (15 mM) in the standard assay incubation gave optimal production of both M3G and M6G by guinea-pig liver homogenates. A number of metal ions were investigated for their ability to inhibit glucuronidation of morphine in both the 3- and 6-positions. Some metal ions, namely Cu+, Cu2+ and Cd2+, were able to inhibit the production of M3G without affecting glucuronidation at the 6-position. Taken together, these data provide further evidence for the existence of UDP-glucuronosyltransferase isoenzymes responsible for the metabolism of morphine. In addition these isoenzymes can be differentially modulated and therefore it is possible to alter the ratio of M3G:M6G formed during in vitro metabolic studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610398     DOI: 10.1016/0006-2952(92)90311-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

2.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  High levels of morphine-6-glucuronide in street heroin addicts.

Authors:  Letizia Antonilli; Federico Semeraro; Carmen Suriano; Luciano Signore; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

6.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

7.  Respiratory effects of chronic in utero methadone or morphine exposure in the neonatal guinea pig.

Authors:  Rosemary T Nettleton; Michael Wallisch; George D Olsen
Journal:  Neurotoxicol Teratol       Date:  2008-03-21       Impact factor: 3.763

8.  A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats.

Authors:  D M Ouellet; G M Pollack
Journal:  J Pharmacokinet Biopharm       Date:  1995-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.